CAS: 1192171-69-9; 4-Chloro-5-(4-((2,6-Dichlorophenyl)Sulfonyl)Piperazin-1-yl)Benzofuran-2-Carboxylic Acid
- 英文名称4-Chloro-5-(4-((2,6-Dichlorophenyl)Sulfonyl)Piperazin-1-yl)Benzofuran-2-Carboxylic Acid
- 中文名称4-氯-5-(4-((2,6-二氯苯基)磺酰基)哌嗪-1-基)苯并呋喃-2-吡唑羧酸
- IUPAC名称4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)piperazin-1-yl)benzofuran-2-carboxylic acid
- 其它别名Vonafexor; 2-Benzofurancarboxylic Acid, 4-Chloro-5-[4-[(2,6-Dichlorophenyl)Sulfonyl]-1-Piperazinyl]-; 4-Chloro-5-(4-((2,6-Dichlorophenyl)Sulfonyl)Piperazin-1-yl)Benzofuran-2-Carboxylic Acid
- CAS编号1192171-69-9
- MFCD编号:MFCD32701906
- FDA UNII编号:XG6DG6A1UN
- 分子式:C19H15Cl3N2O5S分子量:489.76
- 产品CID: 255030
- 同类组份化合物CAS1192171-69-9
- 产品分类Inhibitors/Agonists → Anti-infection → HBV | Inhibitors/Agonists → Metabolic Enzyme → FXR
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2903919090-氯苯
2905110000-甲醇
2912110000-甲醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2021085662-A1
优先权日:2017-03-30
标 题 :Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
发明人：LOTTEAU VINCENT; ANDRE PATRICE
权利人:INST NAT SANTE RECH MED; CENTRE NATIONAL DE LA RECH SCIENFIQUE CNRS; ECOLE NORMALE SUPERIEURE LYON; UNIV CLAUDE BERNARD LYON
摘要:The inventors surprisingly found that FXR plays a determinant role in the maintenance of viral episome in cells from tissues that are not specialized in bile salt synthesis and transport as the liver or the intestine. In particular, the inventors show that FXR agonist could be suitable for inhibiting the replication of viruses (e.g. BKV and HIV-1) that persist in the cell in an episomal and extrachromosomal form of DNA. Accordingly the present invention relates to a method of reducing persistence and expression of an episomal virus in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of a FXR agonist.
专利号:CN-113024552-B
优先权日:2021-03-26
标 题:Synthesis and application of a new class of non-steroidal FXR agonists
专利号:CN-117903036-A
优先权日:2022-10-19
标题:Synthesis and application of a new class of FXR agonists
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, Alkhouri N, Francque S, Girma H, Darteil R, Couchoux H, Wolf M, Sanyal A, Vonderscher J, Scalfaro P. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023 Mar;78(3):479-492. doi: 10.1016/j.jhep.2022.10.023. Epub 2022 Nov 9. 28(12):1690-1698. doi: 10.1111/jvh.13608. Epub 2021 Sep 29.
3: Pan B, Chen S, Zhang Z, Ye D, Zhang X, Yao Y, Luo Y, Wu H, Wang X, Tang N. New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity. Br J Cancer. 2025 Sep;133(5):697-708. doi: 10.1038/s41416-025-03089-z. Epub 2025 Jun 30.
4: Fouillé R, Verrier ER, De Meyer A, Verhoye L, Michelet M, Barnault R, Pons C, Diaz O, Rivoire M, Passot G, Steinmann E, Wedemeyer H, Salvetti A, Pavio N, Doceul V, Darteil R, Meuleman P, Durantel D, Lucifora J. A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses. JHEP Rep. 2025 Feb 28;7(5):101383. doi: 10.1016/j.jhepr.2025.101383.
合成参考文献
参考文献:10.1016/j.biopha.2024.116658
摘要:Tang Y, Fan Y, Wang Y, Wang D, Huang Q, Chen T, Cao X, Wen C, Shen X, Li J, You Y. A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development. Biomed Pharmacother. 2024 Jun;175():116658. doi: 10.1016/j.biopha.2024.116658.
📝 需求与反馈
尽可能描述清楚需求与问题信息
